Vials

Tesamorelin 10mg

Name: Tesamorelin 10mg
Brand: Quanta Pharmaceuticals

A GHRH analogue with the strongest clinical evidence for targeted visceral fat reduction among GH peptides.

Tesamorelin (Egrifta, TH9507) is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, stabilised against rapid enzymatic breakdown. It is the only GHRH analogue with a substantial clinical research record specifically targeting visceral adipose tissue — the fat surrounding internal organs. Independent lab testing confirmed the finished vial at 99% purity with an actual content of 10.23mg against the 10mg label claim.

Verify a product

Independent laboratory documentation

Certificates of Analysis

View the laboratory reports currently published for this product.

Certificate of Analysis

View page 1 View page 2

Specifications

Peptide

Tesamorelin

Also Known As

Egrifta, TH9507

Class

GHRH Analogue

Dosage

10mg/vial

Purity

99%

Verified Content

10.23mg

Sequence

44 Amino Acids

Form

Lyophilised

Half-Life

~26 minutes

Storage

2-8°C

Research Benefits

Visceral fat reduction — Clinical research specifically demonstrates targeted reduction of visceral fat, typically in the 15-20% range.
Endogenous GH pulses — Stimulates the pituitary to release the body's own growth hormone in natural, pulsatile fashion.
IGF-1 elevation — Researched for meaningful, sustained increases in serum IGF-1.
Cognitive function research — Investigated in older-adult research populations for memory and executive function.
Preserves lean and subcutaneous tissue — Effects concentrate on visceral fat without meaningfully affecting subcutaneous fat or lean mass.

How It Works

Tesamorelin is stabilised by a trans-3-hexenoic acid group added to the N-terminus, which dramatically extends its half-life compared with native GHRH, normally degraded within minutes by the enzyme DPP-4. Rather than supplying exogenous growth hormone, it binds GHRH receptors on the anterior pituitary and stimulates the body's own somatotroph cells to release growth hormone in natural, pulsatile bursts, preserving the negative feedback loops from somatostatin and IGF-1.

What distinguishes Tesamorelin within the GHRH category is its specific, clinically studied effect on visceral adipose tissue — the metabolically significant fat surrounding internal organs — via the lipolytic action of pulsatile growth hormone combined with improved insulin signalling in adipose tissue.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. Tesamorelin 10mg must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.